Do GLP-1 analogues have potential as disease-modifying osteoarthritis drugs (DMOADs) in people suffering from OA?
GLP-1 analogues represent a potential new therapeutic opportunity as disease-modifying drugs for osteoarthritis.
The search for new therapeutic targets to treat people suffering from OA remains urgent as there is currently no disease-modifyingtherapy available for this disease. This review discusses how GLP-1 analogues could be potential DMOADs for treating OA thanks to their anti-inflammatory, immunoregulatory and differentiation properties.
Meurot et al. (Sat,) studied this question.